Supporting someone with ovarian cancer does not require perfect words. It means listening, offering practical help, respecting what she needs, and continuing to show up long after the first difficult conversations.

Two recent publications coauthored by WCRF leaders John P. Micha, M.D., and Bram Goldstein, Ph.D., examine molecular residual disease testing in early-stage breast cancer and surgical approaches in advanced-stage ovarian cancer.

Ovarian cancer is most often diagnosed later in life, but awareness matters at every age. Younger women should understand the symptoms, know what routine screenings can, and can't, detect, and feel comfortable speaking with a doctor when something does not feel right.

Bram Goldstein, Ph.D., provides clinical context on encouraging research examining how mortality risk changes for long-term ovarian cancer survivors who remain disease-free.

Bram Goldstein, Ph.D., provides clinical context on research examining racial and ethnic disparities in epithelial ovarian cancer survival and the need for further study.

Bram Goldstein, Ph.D., provides clinical context on research indicating that fallopian tube removal during another planned surgery may significantly reduce the risk of certain ovarian cancers.

What does a Stage 0 breast cancer diagnosis mean? Bram Goldstein, Ph.D., provides clinical context on DCIS, early detection, treatment, and the research supporting more individualized care.

Awareness can start important conversations, but research is what moves those conversations forward. Learn how women’s cancer research supports progress in prevention, detection, treatment, survivorship, and quality of life.

Where people turn for cancer information, and how much they trust those sources, can shape what they understand about HPV and cervical cancer. This research examines the connection between trust in physicians and public health agencies and awareness that HPV is a leading cause of cervical cancer.

Cervical cancer is the fourth most frequent cancer and fourth leading cause of death in women. In 2020, 604,000 new cases and 342,000 deaths worldwide were estimated. A recent study endeavored to identify the association between BMI and cervical cancer and precancerous cervical lesions (PCL) in screened women.

Obesity is well established as a risk factor for endometrial cancer, also driving higher mortality rates among these patients. Previous research conducted at the University of Bergen had shown that relying solely on body mass index (BMI) to estimate obesity-related risk factors is insufficient. Instead, they found that a higher percentage of visceral fat is associated with poorer outcomes in endometrial cancer patients.

Rising rates of early-onset cancer have generated substantial and hence, clinical guidelines have shifted to recommend earlier screening for some cancers.